Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.


Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Are you more likely to perform partial rather than radical nephrectomy for tumors if robotic-assisted surgery is available?

Are you more likely to perform partial rather ...

Availability of robotic-assisted surgery at a hospital was independently associated with greater use of partial nephrectomy.

What proportion of your hospitalized patients is cared for by hospitalists?

What proportion of your hospitalized patients is cared ...

More and more inpatient care is being provided by hospitalists.

Has the proportion of your patients undergoing prostate brachytherapy been declining?

Has the proportion of your patients undergoing prostate ...

Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.